Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

In the study, most participants are aged 18-60, with 53% female and 73.1% carrying the c.826C>A mutation, while 15 patients are aged 12-18.

Baseline Characteristics and Updates for Phase 3 FORTIFY Study of BBP-418 in LGMD

A recent study shows that eteplirsen, a drug promoting dystrophin production, significantly slowed the decline in heart function, specifically left ventricular ejection fraction, in patients with Duchenne muscular dystrophy.

Eteplirsen Treatment Significantly Slows Heart Function Decline in Duchenne Muscular Dystrophy

Spanning 14 weeks, the study evaluates age-appropriate dosing, safety, pharmacokinetics, and clinical effects through once-weekly injections of efgartigimod PH20 SC in juvenile myasthenia gravis.

New Study to Test Subcutaneous Efgartigimod PH20 in Juvenile Myasthenia Gravis

Videos

Experts in sleep medicine discuss the detrimental effects of daylight saving time on sleep, health, and public safety, advocating for the adoption of permanent standard time. [WATCH TIME: 5 minutes]

The Case for Permanent Standard Time: Clinical and Public Health Implications

Kathleen Costello discusses her new role as interim CEO of the CMSC. She has the support of Jeff Wilken, CMSC president, and Tina Trott, CMSC director.

Continuing the Vision of June Halper: What's Next for CMSC

Interim chief executive officer of the Consortium of Multiple Sclerosis Centers.

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

What to Expect From the 2025 CMSC Annual Meeting: Kathleen Costello, CRNP, MSCN

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital delved into the unique challenges and research objectives surrounding MOG antibody-associated disease. [WATCH TIME: 3 minutes]

Challenges and Research Priorities for Pediatric MOGAD: Kelsey Poisson, MD

, has been with the team since September 2022. Follow her on Twitter 

The professor of neurology at Northwestern University Feinberg School of Medicine discussed the NSD-ISS and its potential to refine PD diagnosis and clinical trial selection through biomarker-driven staging.

NeuroVoices: Tanya Simuni, MD, FAAN, on Using the Neuronal α-Synuclein Disease Integrated Staging System Framework to Advance Parkinson Disease Staging

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

ISC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Peer Exchange

1rem

Recommendations for selecting and sequencing therapies used to treat patients with relapsing multiple sclerosis.

Optimal Management of Relapsing Multiple Sclerosis:  Advanced Practice Providers Perspectives

Fred D. Lublin, MD; Ravi Dukkipati, MD; Gavin Giovannoni, MD; and Lauren Gluck, MD explore several topics pertaining to the diagnosis and treatment of relapsing multiple sclerosis (MS), including current treatment options, therapy sequencing, and the future of MS management.

Optimal Management of Relapsing Multiple Sclerosis 

Neurology experts discuss the diagnosis and treatment of advanced Parkinson disease.

Recognizing and Managing Advanced Parkinson Disease 

Panelists discuss recommendations for the diagnosis, treatment, and management of patients with Dravet Syndrome.

Redefining Treatment Outcomes in Dravet Syndrome

Recommendations for appropriate treatment selection and use of high efficacy therapies as treatment for relapsing-remitting multiple sclerosis.

Strategies in Treating Relapsing-Remitting Multiple Sclerosis

Crystal Proud, MD; Claudia Chiriboga, MD, MPH; Tom Crawford, MD; Basil Darras, MD; and Carolina Tesi Rocha, MD provide a discussion on the importance of early diagnosis and treatment of spinal muscular atrophy and consider data from recent clinical trials of disease-modifying therapy options. 

The Changing Landscape in the Treatment of Spinal Muscular Atrophy

Richard S. Bedlack, MD, PhD, MS; Ammar Al-Chalabi, MB, ChB, PhD; Jinsy A. Andrews, MD, MSc; and Jeremy M. Schefner, MD, PhD discuss the current treatment landscape for amyotrophic lateral sclerosis (ALS) and provide insights into ongoing clinical trials and recent results. 

Progress in the Treatment of Amyotrophic Lateral Sclerosis (ALS) 

Experts discuss the diagnosis and treatment of progressive multiple sclerosis.

Management of Progressive Multiple Sclerosis

Key insight into treating ATTR Amyloidosis, including the use of new therapeutic options to provide a practical perspective on how recent data may apply to your clinical practice. 

Recent Advances in the Treatment of Hereditary ATTR Amyloidosis (hATTR)  

Fred Lublin, MD; Patricia K. Coyle, MD; Mark Freedman, MD; and Scott D. Newsome, DO, discuss a number of topics pertaining to the diagnosis of multiple sclerosis, including a focus on fatigue and its impact on quality of life.

Updates in the Management of Relapsing Multiple Sclerosis

Advances in the Management of Acute Treatment of Migraine

Global Approaches to the Management of Relapsing Multiple Sclerosis

Management of Cardiac Amyloidosis 

Advances in the Treatment of Spinal Muscular Atrophy

Management of Narcolepsy and Excessive Daytime Sleepiness

Updates to the MRI Protocol and Clinical Guidelines for MS: CMSC Working Group

Advances in Early Treatment Approaches in Multiple Sclerosis

Managing OFF Episodes in Parkinson Disease

Advances in the Treatment of Alzheimer

Treatment of Multiple Sclerosis Relapses

New Paradigms: Preventive Treatment for Chronic Migraine 

Dravet Syndrome and Lennox-Gastaut Syndrome: Recent Treatment Advances

Understanding Spinal Muscular Atrophy (SMA) and the Recent Advances in Management

Understanding Hereditary ATTR (hATTR) Amyloidosis and the Recent Advances in Management

Advances in the Diagnosis and Management of Multiple Sclerosis

Epilepsy: Current Trends and Treatments for Focal Seizures